Difluoromethane (HFC32) is under development as a replacement for chlorofluorocarbons (CFCs) in some refrigeration applications. It has been evaluated by standard studies of toxicity, developmental toxicity, and genotoxicity. In addition, the metabolism and disposition of HFC32 was investigated and a physiologically based pharmacokinetic (PB-PK) model constructed. Inhalation of HFC32 (up to 50,000 ppm) caused no organ-specific effects, but resulted in slight maternal toxicity to the pregnant rat and rabbit and some fetotoxicity to the rat. HFC32 did not sensitize the heart to adrenaline. The pharmacokinetics of [ 14 C]difluoromethane (10,000 to 50,000 ppm/6 hr) revealed that about 2.1% of the inhaled HFC32 was absorbed and that steady state blood levels were achieved within 2 hr and were proportional to dose. Carbon dioxide was the major metabolite of HFC32 at all exposure levels. Carbon monoxide was not detected. The in vivo data were used to validate a PB-PK model to describe the uptake and metabolism of HFC32. Absorption and distribution are adequately described using rat blood:air and tissue:air partition coefficients. Metabolism, which was linear across the dose range, was described by a first order rate constant (K f = 8.98 hr" 1 ). Of the absorbed HFC32, about 63% was metabolized at all doses; however, when metabolism was expressed as a percentage of the inhaled dose it was much lower, being about 1.4% of the HFC32 entering the airways. Overall, the results indicate that HFC32 is of very low toxicity and should be an acceptable alternative to CFCs. © 1996 society of Toxi col ogy In order to replace chlorofluorocarbons which can contribute to ozone depletion in the stratosphere (World Meteorological Organization, 1991), a number of hydrofluorocarbons have been developed which have no ozone depleting potential. Difluoromethane (HFC32) has been developed for use in low temperature refrigeration applications.
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Toxicological data on HFC32 is sparse, but this fluoro- ' To whom correspondence should be addressed.
carbon was of low inhalation toxicity upon 10-day exposure to rats (Trochimowicz et al., 1977) . Similarly, an investigation of the uptake and metabolism of HFC32, using a gas mixture containing this fluorocarbon, suggested that uptake is limited. Consequently a rate for metabolism was not quantified, being below the limits of detection for the techniques used (Gargas et al, 1986) . As HFC32 is a gas, occupational exposure is most likely to be to vapor and studies in animals should use the inhalation route of exposure. The toxicological evaluation of HFC32 reported here has included standard assessments to international guideline protocols of acute to subchronic inhalation toxicity, developmental toxicity, and short term tests of genotoxic potential. As several alkanes and haloalkanes are known to affect the sensitivity of the heart to adrenaline (Reinhardt et al., 1971) , an assessment of this activity was made on HFC32. Furthermore, blood levels, metabolism, and excretion of this fluorocarbon following inhalation exposure at concentrations similar to those used in the toxicity assessment were measured. In addition, measurement of rat blood:air and tissue:air partition coefficients allows development of a physiologically based pharmacokinetic (PB-PK) model to quantitatively determine the in vivo absorption and metabolism of HFC32.
MATERIALS AND METHODS
Difluoromethane (bpt: -50°C) with a minimum purity of 99.94% was supplied as a colourless liquified gas by ICI Chemicals and Polymers Ltd. (Runcorn, UK). [
14 C]Difluoromethane ([ H C]HFC32) with a specific activity of 19.0 mCi/mmol was obtained from Cambridge Research Biochemicals Ltd. (Billingham, UK). The radiochemical purity, determined by radio gascnromatography was >97% and the chemical purity, determined by gas chromatography-mass spectroscopy, was >95%. Hopcalit catalyst was obtained from Dragerwerke AG (Lubeck, Germany). All other chemicals were of analytical grade or of the highest purity available.
Animals
Virgin female New Zealand white rabbits (16-24 weeks of age) were supplied by Interfauna UK (Huntingdon, UK). Approximately 2 weeks prior to shipment, each rabbit was given an intravenous injection of 25 IU chorionic gonadotropin [Profast 500, Serono Laboratories (UK) Ltd.] to promote ovulation prior to insemination. Upon arrival, animals were housed individually in temperature controlled rooms (15-19°C, relative humidity 55-90%) as described in Collins et al. (1995) .
Wistar rats (Alpk:APfSD strain) were supplied by the Barriered Animal Breeding Unit, Zeneca Pharmaceuticals (Macclesfield, UK). Rats were 22 days of age for the repeat exposure toxicity study, 11 weeks of age for the developmental toxicity study, and 6 to 8 weeks of age for the metabolism study. CD-I mice (6 to 8 weeks of age) were supplied by Charles River (Margate, UK). Eight male purebred beagle dogs (6 to 7 months of age) were supplied by Interfauna UK and housed singly or in pairs for 2 weeks for acclimatization. All animals were housed in temperature controlled rooms (19-23°C) with relative humidity between 40 and 70%. Rats and mice were provided with food and water ad libitum except during exposure, whereas, dogs were fed once daily.
Inhalation Toxicity Studies
Atmosphere generation and analysis. Test atmospheres were generated by passing liquid HFC32 into a copper coil placed in a water bath maintained at approximately 45°C. The resultant vapor was passed through a copper equilibrium coil and diluted by addition of filtered, dried air before passage into the exposure chambers. Test atmospheres were sampled using an automatic air sampling system and analyzed using gas chromatography (see below). Control atmospheres and room air were also sampled and analyzed.
Acute toxicity. Male and female rats (n = 5 per exposure group) were exposed nose-only for a single 4-hr period to HFC32 at atmosphere concentrations of 7,500, 86,000, and 520,000 ppm (O 2 concentration maintained at 19%) and then observed for 14 days, after which time a limited postmortem examination was made. Responsiveness to sound was assessed by observing the reaction to a tap on the wall of the exposure chamber.
Cardiac sensitization.
The potential for cardiac sensitization was assessed in the beagle dog (n = 8), as this species can be trained to the procedure and provides suitable electrocardiograph data. The protocol was that of Reinhardt et al. (1971) as modified by Hardy et al. (1994) . Before the test, the cardiac response of each animal to adrenaline administered intravenously was determined to give the dose that resulted in a few ectopic beats only. This dose was used for subsequent studies with that individual animal. Test atmospheres were administered by face mask and the ECG was recorded throughout. Initially an adrenaline challenge was administered in the presence of air alone. Then, test gas was administered for 5 min and adrenaline administered again. The ECG was inspected and a positive effect was defined as the appearance of a burst of multifocal ventncular ectopic activity or ventricular fibrillation. Ventricular tachycardia alone was not definitive of a positive response. Each dog was assessed for its responsiveness to 20,000 or 25,000 ppm atmospheres of the known sensitizer trichlorofluoromethane, to show their suitability for the test. Subsequently, HFC32 was administered at 150,000 ppm then at 50,000 ppm increments to a maximum of 350,000 ppm.
Repeat exposure toxicity. Male and female rats (n = 10 per exposure group) were exposed to 5,000, 15,000, or 50,000 ppm HFC32 for 6 hr/day, 5 days/week for 13 weeks. Concurrent groups were exposed to air only. Experimental procedures and measurements were conducted as described by Collins et al. (1995) and included measurement of hematological parameters in blood and clinical chemistry on plasma, after 5 and 13 weeks of exposure. After the last exposure, animals were anesthetized with Fluothane (Zeneca Pharmaceuticals) and killed by exsanguination. Adrenal glands, brain, heart, kidneys, liver, lungs, spleen, and testes were removed, weighed, and fixed in Bouin's solution. Other tissues (Collins et al., 1995) were taken and fixed without weighing. Tissues from control animals and those exposed to 50,000 ppm were routinely processed in paraffin wax and 5-fim sections cut and then stained with hematoxylin and eosin. All sections were examined by light microscopy.
Developmental toxicity. Developmental toxicity was assessed in rats (n = 24) and rabbits (n = 24) exposed to HFC32 at concentrations of 5,000, 15,000, and 50,000 ppm for 6 hr per day from Days 6 to 15 (rats) or 6 to 18 (rabbits) of gestation, the day of mating being defined as Day 0. Animals were observed daily, and body weight and food consumption were measured periodically during gestation. On Day 21 (rats) and Day 29 (rabbits) animals were humanely killed and subject to gross postmortem examination. The uterus was examined for live fetuses and early and late fetal deaths, and then weighed. Live fetuses were killed by barbiturate injection, weighed, and examined for external and visceral abnormalities. During further standard processing the brain and the skeleton were stained and examined. Fetal observations were classified as major deviations for a permanent structural or functional change considered likely to be fatal. Small and generally transient deviations, likely not to be fatal and frequently representing delayed development, were classified as minor deviations. Variants were a minor classification for observations occurring more frequently in control animals. Maternal and fetal data were subject to statistical analysis to determine significance of any differences from control. Further details have been reported by Collins et al. (1995) .
In vivo and in vitro genotoxicity tests. The bacterial mutagenicity assay of Maron and Ames (1983) was used to evaluate reverse mutations in both the absence and presence of an exogenous metabolic activation system of mammalian enzymes (S9). Salmonella typhimurium (TA98, TAI00, TA1535, and TA1537) and Escherichia coli (WP2P and WP2P uvrA) were exposed to HFC32 at concentrations from 5 to 100% (v/v) in closed vessels at 37°C for a duration of 3 days
In vitro cytogenetic assays were conducted using human lymphocytes and Chinese Hamster lung cells as described by Collins et al. (1995) . The cultures from both male and female donors were harvested at 72 hr and cultures from the female donor, exposed to 100% HFC32, were also harvested at 96 hr. The Chinese hamster lung cells were exposed to HFC32 at concentrations ranging from 10 to 80% (v/v) both in the presence and absence of S9.
A mouse micronucleus assay was conducted following exposure of male and female mice (n = 5 per exposure group), in all glass chambers, to HFC32 at a concentration of 132,000 ppm for 6 hr. A concurrent control group was treated similarly but exposed to air only. The animals were killed 24 and 48 hr after exposure. Slides of bone marrow were prepared and stained. One thousand polychromatic erythrocytes were counted for each animal and the number with micronuclei was recorded and the percentage of polychromatic to normochromatic erythrocytes was determined.
Metabolism and Pharmacokinetic Studies
The inhalation chamber and metabolism cages were housed inside an efficiently ventilated fume cupboard to prevent exposure of personnel to
Rats were exposed to HFC32 or [ I4 C]HFC32 at nominal concentrations of 10,000, 25.000, and 50,000 ppm. The concentration of fluorocarbon was monitored throughout the exposure by gas-chromatography using a GCD gas chromatograph (PYE Unicam Ltd., Cambridge, UK) with FID detection and fitted with a glass column (1.5 m length, 2 mm i.d.) containing Poropak PS (80-100 mesh) with nitrogen as the carrier gas at a flow rate of 20 ml/min (temperature: injector, 100°C; column oven, 50°C: detector, 250°C). The retention time of HFC32 was 57 sec. The specific activity of [ 14 CJ-HFC32 in the chamber was determined following liquid scintillation counting.
Metabolic fate and disposition of ["C]HFC32.
Rats (n = 4) were singly exposed whole body for 6 hr to an atmosphere of 10,000 ppm (silica gel dried) was drawn through the chamber at a rate of 1 liter/min for the period of expired air collection after which the lid was replaced by a perforated grid for the remaining duration of the study. Urine and feces were collected into containers cooled in dry ice. Samples were stored at -20°C prior to the quantification of radiolabel content. I4 CO 2 was collected by dissolution into 2 M sodium hydroxide (2 M NaOH). '"CO was collected by passage through Hopcalit catalyst (10 g) to oxidize it to I4 CO 2 which was then trapped in 2 M NaOH.
14 CO 2 and 14 CO traps were stored at 4°C prior to assay for radioactivity. Expired [ I4 C]HFC32 was collected by dissolution into dry-ice cooled acetone. A trap (cooled in dry-ice) was placed in series before and after the acetone trap to condense water vapor and acetone vapor, respectively. Samples were stored at -70°C prior to assay for radioactivity. The efficiency of the acetone traps was >99%.
At termination (4 days), the rats were anesthetized with halothane vapor and killed by either cardiac puncture or cervical dislocation. One rat was assayed for total carcass radioactivity. The remaining three animals were dissected and the following tissues removed and assayed for radioactivity: whole blood, plasma, liver, kidney, heart, lungs, brain, testes, muscle (femoral), renal fat, spleen, and bone (femur).
Determination of exhaled 14 CO 2 profiles. Rats (n = 3) were group exposed to [ 14 C]HFC32 at concentrations of 10,000, 25,000, and 50,000 ppm for 6 hr and exhaled I4 CO 2 was measured during the exposure and up to 11.5 hr postexposure (see above).
Determination of radioactivity in expired air, excreta, tissues, and carcass. Radioactivity in all samples was measured in duplicate using a Tricarb 2000CD Liquid Scintillation System (Packard Ltd.). Weighed aliquots of urine (200 ^1) were assayed in Optiphase "MP" (10 ml). Expired 14 CO 2 and I4 CO were measured in aliquots of 2 M NaOH (2 ml) in Hionic Fluor (20 ml). Expired radiolabeled organic material was determined by taking aliquots of acetone (1 ml, at -70°C) and counting them in Optiphase "MP" (10 ml). Fecal samples were homogeneously mixed with an equal weight of anhydrous MgSO 4 . Weighed aliquots were oxidized using a Packard Sample Oxidizer Model 307 followed by liquid scintillation counting. Samples were assayed in a mixed scintillation cocktail containing Carbo-Sorb E (8 ml) and Permofluor E (12 ml).
Samples of liver homogenate, muscle, renal fat, and whole kidneys, lungs, brain, heart, and testes were each solubilized in a volume four times their own weight of Soluene 350 (minimum volume 1 ml). Aliquots of digest (normally 1 g) were counted in Hionic Fluor (20 ml). Spleen (homogenized with an equal weight of water or spleen alone), whole blood, and bone were sample oxidized (see fecal analysis). Carcass digestion was achieved using the method described by Ellis et al. (1993) . Plasma (200 /xl) was analyzed in Optiphase "MP" (10 ml).
Carboxyhemoglobin determination.
Rats (n = 4) were housed in an inhalation chamber and group exposed for 6 hr to an atmosphere of 10,000 ppm HFC32. Naive rats (n = 4) were used as controls. At the cessation of exposure all animals were anesthetized with halothane vapor and killed by cardiac puncture. Blood was collected in EDTA-treated syringes and immediately analyzed for carboxyhemoglobin content using a IL282 Co-Oximeter.
Determination ofHFC32 blood levels. Rats (n = 3 per exposure group) were exposed to HFC32 for 2, 4, and 6 hr at atmosphere concentrations of 10,000, 25,000, and 50,000 ppm. After treatment, rats were killed by a slowly rising concentration of CO 2 followed by cardiac puncture. This was achieved by substituting the air intake to the chamber with CO 2 (flow rate 1 liter/min) while maintaining the flow of fluorocarbon. This arrangement ensured that the blood:air distribution of the fluorocarbon was maintained prior to cardiac puncture. The blood was collected in lithium heparin tubes and analyzed immediately for HFC32.
Blood (1-2 g), collected by cardiac puncture into lithium heparin tubes, was injected into Reacti-Vials (containing lithium heparin beads to prevent clotting) fitted with teflon-coated rubber septa pierced with a side-port needle to relieve internal pressure build-up. The side-port needle was immediately removed following blood addition and the vials placed on a blood roller at room temperature for 2 hr to equilibrate the fluorocarbon between the blood and head-space. Head-space analysis established that equilibration was attained by 2 hr.
The blood concentration of HFC32 ([blood] ^ig/ml) was derived from the amount of HFC32 in the head-space at equilibrium and the blood:air partition coefficient at the equilibration temperature (f W ood = 1.44 ± 0.08 at 21°C):
where [air] is the amount of HFC32 in the head-space (nmol), V^ is the head-space volume (ml), V bk)od is the blood volume (ml), and FW is the formula weight of HFC32.
Determination of partition coefficients. Rat liquid:air and tissue:air partition coefficients for HFC32 were determined by a modification of the reported procedure of Gargas et al. (1989) . The liquids and tissues utilized were heparinized blood (2 ml), 0.9% sodium chlonde solution (4 ml), reagent grade olive oil (2 ml), liver (0.5 g), and fat (1.5 g). The latter two tissues were homogenized in 0.9% saline (1:3 w/v). Reacti-Vials (internal volume ~12 ml) fitted with Teflon-coated rubber septa were used as the equilibrium vessels. Vials containing test liquid or tissue and HFC32 (head space concentration ~38,000 ppm) were placed on a blood roller housed in a thermostated chamber at 37°C to reach thermal equilibrium. Headspace analysis established that equilibrium was attained by 2 hr.
In vitro conjugation ofHFC32 catalyzed by the theta class glutathione-S-transferases (0-GSTs).
Rat liver cytosol enriched with glutathione-Stransferases of the theta class (#-GSTs) was obtained as described by Meyer et al. (1991) . The conjugation of HFC32 with glutathione (GSH) was studied at 37°C in incubates containing a 44 fiwi solution of fluorocarbon in 0.2 M sodium phosphate buffer (pH 7.4), 1 mM GSH, and 0-GST-enriched cytosol fraction (0.34 mg protein/ml of incubate). The conjugation of chlorofluoromethane (HCFC31, 1.2 mM solution in 0.2 M sodium phosphate buffer, pH 7.4) and dichloromethane (DCM, 10 mM solution in 0.2 M sodium phosphate buffer, pH 7.4) was also studied. The reaction was assessed by measunng the rate of formation of formaldehyde (Nash, 1953) , which is released as a result of hydrolysis of the GSH conjugate, over a period of 1 hr.
Physiologically Based Pharmacokinetic (PB-PK) Modeling of HFC32
A PB-PK model was constructed using the ACSL (Advanced Continuous Simulation Language) computer program to describe the uptake of inhaled HFC32 from the lung into blood, its distribution to body compartments combined in groups displaying similar uptake, and perfusion characteristics and metabolism. Metabolism was assumed to occur only in the liver compartment and was adequately described m the model by a first-order rate constant (K f ). The model, which was based on that constructed by Andersen et al. (1987) for DCM and Ramsey and Andersen (1984) for styrene uses physiological parameters taken from Anderson et al. (1987) and FiserovaBergerova (1983) (Table 1 ). The partitioning of HFC32 into blood and tissues was described using experimentally measured liquid:air and tissue:air partition coefficients. Uptake, or absorption, of HFC32 from the alveolar air space was expressed as the sum of the concentrations in the tissue compartments at the end of the exposure (6 hr) plus the amount metabolized to CO 2 and urinary metabolites.
RESULTS

Inhalation Toxicity Studies
There were no deaths as a consequence of a 4-hr exposure to HFC32 at a concentration of 520,000 ppm. The only treatment related effects were signs of central nervous sys- Gargas et al. (1986). tern depression, such as reduced response to sound stimuli, at 86,000 ppm and above. These effects were temporary, the animals recovering quickly on cessation of exposure.
There was no evidence of increased sensitivity of the heart to adrenaline in dogs exposed to HFC32 at concentrations between 150,000 and 350,000 ppm.
With repeated exposure of rats to concentrations of up to 50,000 ppm HFC32 for 13 weeks there were no treatmentrelated effects on clinical signs, body weight gain, and hematological, plasma, and clinical chemistry parameters. At postmortem examination there were no dose-related changes in organ weights and no treatment related histological changes seen by light microscopy in tissues from rats exposed to 50,000 ppm HFC32.
In the developmental toxicity study in the rat, maternal body weight gain was similar to control at all exposure levels, but there was a slight reduction of maternal food consumption at 50,000 ppm which may indicate some maternal toxicity (Table 2 ). Fetus number, growth, and survival in utero were not affected by treatment. Lower numbers of Corpora lutea and increased preimplantation loss in animals exposed to 15,000 and 50,000 ppm resulted in reduced fetal numbers in these groups (Table 3) . However, these events occurred before exposure commenced on Day 7 and were thus not due to HFC32 exposure. The incidence of some minor defects or variants was increased at 50,000 ppm HFC32. The increase was due to the number of fetuses with slightly dilated ureters, mottled livers, or cysts attached to livers. Considered individually these findings were not significantly different from controls. There was also a statistically significant increase in external/visceral variants in the high exposure group. Evaluation of specific findings revealed the increase to be predominantly of kinked ureters. These findings are indicative of minimal fetal toxicity. There was no evidence of a teratogenic effect. In the pregnant rabbit, the only effect was a slight loss of body weight during Days 8 to 10 of gestation at 50,000 ppm HFC32. There was no evidence of fetal toxicity or teratogenicity in the rabbit at exposures up to 50,000 ppm HFC32.
Genetic Toxicity Studies
HFC32 exerted no genotoxic activity in any of the tests. HFC32 was not mutagenic in the Ames test and it was not clastogenic in human lymphocytes or in Chinese hamster lung cells. There was no increase in micronucleated polychromatic erythrocytes in the bone marrow of mice exposed to 132,000 ppm HFC32. In all studies, positive controls reacted appropriately showing the test systems to be valid.
PB-PK Modeling
A PB-PK model was constructed using physiological parameters described by Anderson et al. (1987) and FiserovaBergerova (1983) and validated using experimental data, to quantitatively determine the in vivo uptake and metabolism of HFC32 in the male rat (Fig. 1 ). In the model, the uptake of HFC32 from the alveolar air space of the lung into blood was described by the blood:air partition coefficient. Similarly, the distribution of HFC32 into body compartments was described by the partitioning of HFC32 from blood into tissues. The rat HFC32 bloodrair and tissue:air partition coefficients are given in Table 1 and are comparable to those quoted by Gargas et al. (1986) . A comparison of the HFC32 steady state blood levels predicted by the PB-PK model with those measured experimentally showed that the model provides an accurate simulation of the uptake process (Table 4) . From experimentally derived data, steady state blood levels were attained by 2 hr and increased linearly with exposure concentration (Table  4 ). Blood HFC32 concentrations were not determined postexposure; however, at the end of a 6-hr exposure at 10,000 ppm [
I4 C]HFC32 the fluorocarbon retained by the animal was eliminated rapidly in exhaled air (Fig. 2) . At this exposure level, unchanged HFC32 accounted for about 28% of the total radiolabel recovered (Table 5) . 
The Pharmacokinetics and Metabolism of [ N C]HFC32
The distribution of radiolabel derived from HFC32 in rats exposed at a concentration of 10,000 ppm for 6 hr is shown in Table 5 . The majority of radiolabel was exhaled as CO 2 and to a lesser extent unchanged HFC32. There were minimal amounts of radiolabel in urine, feces, and carcass.
Exhalation of CO 2 . CO 2 was the major metabolite of HFC32 and accounted for 56.2% of total radiolabel recovered (Table 5 ). The amount of HFC32 metabolized to CO 2 increased linearly with dose (10,000 to 50,000 ppm) and the maximum rate of elimination, measured during the period 4-6 hr of exposure, was about 125, 355, and 667 //mol/kg bwt/hr at 10,000, 25,000, and 50,000 ppm, respectively. A comparison of the area under the 14 CO 2 exhalation curves gives a ratio of 1:3.1:5.6 confirming that metabolism to CO 2 had not saturated over the range of exposures chosen for the study (Fig. 3) . Exhalation of CO. This study produced no evidence of CO formation from HFC32. Carboxyhemoglobin levels in the blood of rats exposed to this fluorocarbon at 10,000 ppm for 6 hr were 2.5 ± 0.2%, whereas control blood gave values of 2.0 ± 0.4%.
Excretion of HFC32 metabolites in urine and feces. In addition to the exhalation of CO 2 , nonvolatile metabolites of HFC32 were excreted by the rat in urine and feces. Excreta was collected during a 6-hr exposure to [ I4 C]HFC32 at a concentration of 10,000 ppm and up to 96 hr postexposure. The excretion of radiolabel was rapid, the majority being eliminated within 24 hr of the end of exposure (Fig.  4) . Total radiolabeled material excreted in urine and feces accounted for 7.5 and 1.7% of total radiolabel recovered, equivalent to 10.5 and 2.4%, respectively, of total metabolites recovered in urine, feces and exhaled air at this exposure level (Table 5) .
Urine samples were also collected during a 6-hr exposure and up to 11.5 hr postexposure to concentrations of 10,000, 25,000, and 50,000 ppm [ 14 C]HFC32 for the purpose of comparing total metabolism at these dose levels. The amount of radiolabel recovered in urine was equivalent to 96.3, 252.8, and 358 .0 Atmol/kg bwt at the 10,000, 25,000, and 50,000 ppm dose levels, respectively. Urinary radiolabel collected up to 11.5 hr following a 10,000 ppm exposure accounted for about 80% of that collected with the longer 96-hr postexposure period used in the previous experiment. Thus, if the data are corrected by this factor the total urinary excretion is estimated to be 120, 316, and 447 ^mol/kg bwt at the 10,000, 25,000, and 50,000 ppm dose levels, respectively.
The amount of radiolabel remaining in the whole carcass at 5 days postexposure to [ I4 C]HFC32 at 10,000 ppm was small (Table 5) . Analysis of a range of tissues (Table 6) showed a relatively uniform distribution of radiolabel with the highest concentration in the lung. There was no evidence for specific uptake into any organ or tissue.
To establish the amount of HFC32 metabolized, the dose of fluorocarbon received during a 6-hr exposure was expressed both as the inhaled dose (the amount of fluorocarbon available for absorption in the respiratory tract over the exposure period) and the absorbed dose (the amount of fluorocarbon entering systemic circulation). The doses of HFC32 inhaled at exposures of 10,000, 25,000, and 50,000 ppm were obtained using the procedure reported by Ellis et al. (1993) using allometric equations for the rat described by Guyton (1947) and are given in Tables 4 and 5 . The absorbed dose of HFC32 was obtained from the PB-PK model and was expressed as the total fluorocarbon in the tissue compartments at the end of the exposure (determined from blood:air and blood:tissue partition coefficients) and the amount metabolized to CO 2 and urinary metabolites. The absorbed dose was predicted by the model to increase linearly with increasing exposure concentration and accounted for approximately 2.1% of the HFC32 inhaled (Table 4) .
Since it has been established that the excretion of radiolabel by the fecal route is minimal and that the radiolabel retained by the carcass is low, total metabolism can be as- Note. Data are Mean ± SD (n = 4) except for CO? quantitation where the value is a mean of three animals (see Fig. 3 ). Radioactivity remaining in the whole carcass is determined from a single animal. Values in parentheses are percentages of radioactivity recovered.
sumed to be composed predominantly of that radiolabel exhaled as CO 2 and that found in urine. With this assumption, the total metabolism resulting from a 6-hr exposure to HFC32 at concentrations of 10,000, 25,000, and 50,000 ppm increased proportionally with dose, and was estimated to be 0.94, 2.85, and 5.05 mmol/kg bwt, respectively. From these values it is estimated that about 90% of the metabolized HFC32 was exhaled as CO 2 . The metabolism of HFC32 was predicted by the PB-PK model to be flow limited, that is, the rate of HFC32 reaching the liver was limited by the low blood:air partition coefficient. Maximal metabolic rates were not achieved up to the highest dose level of 50,000 ppm. Metabolism was linear throughout the dose range and was described in the model by a linear rate constant, K f ( Table  1 ). The amount of HFC32 predicted to be metabolized by the PB-PK model (urinary metabolites and CO 2 ) was in good agreement with the experimental values and the comparison is shown in Table 4 . From the model it can be determined that about 63% of the absorbed dose was metabolized throughout the dose range. However, metabolism expressed as a percentage of the inhaled dose was much lower, being approximately 1.4% of the dose entering the airways.
Metabolism by 6-GSTs. The potential for the 0-GSTs to catalyze the glutathione conjugation of HFC32 was assessed against HFC31 and DCM. Formaldehyde production from HFC31 and DCM was 1.18 ^g/min/mg of protein, whereas under comparable conditions metabolism of HFC32 could not be detected.
DISCUSSION
The acute and repeat exposure toxicity of HFC32 has been investigated alongside its pharmacokinetics and metabolism in the rat. At concentrations of about 100,000 ppm there is evidence of central nervous system effects, as is commonly seen with alkanes and haloalkanes. It is notable that no organ-specific effects related to HFC32 were seen in toxicity studies at concentrations up to 50,000 ppm. In developmental toxicity studies there was evidence of slight maternal toxicity at this concentration in the rat resulting in slight fetotoxicity. However, there were no developmental effects seen. HFC32 did not sensitize the heart to adrenaline even at very high exposure concentrations, in contrast to several other alkanes and haloalkanes (Reinhardt et al, 1971; Hardy et al., 1994) . This is in accordance with the observation of Hardy et al. (1994) that highly fluorinated alkanes do not have strong cardiac sensitization potentials. HFC32 exhibited no genotoxic activity in a number of predictive tests.
The disposition and metabolism of HFC32 was investigated at exposure concentrations near and up to the maximum used in the toxicity studies. The HFC32 rat bloodrair partition coefficient of 1.25 ± 0.17 is significantly lower than that of any other dihalomethane (HCFC31, 5.1 and DCM, 19.4, Gargas et al., 1986) . Consequently, uptake of HFC32 from the alveolar airspace into blood is comparatively low and is the rate limiting parameter for all other processes, including metabolism. Furthermore, HFC32 is not significantly soluble in fat and is not stored in the fat compartment during or postexposure. The partition coefficients for other body compartments were also comparable to the blood:air partition coefficients (Table 1) .
HFC32 steady state blood levels were attained within 0-2 hr of exposure, well within the exposure duration for the toxicity studies, and were proportional to dose. Upon cessation of exposure, elimination of HFC32 was rapid (Fig.  2) . The experimentally measured blood levels were accurately predicted by the PB-PK model (Table 4 ). Sensitivity analysis showed that the blood levels were controlled almost entirely by the blood:air partition coefficient and were not affected by any other physiological or metabolic parameter.
The amount of HFC32 metabolized increased linearly throughout the dose range studied and was dependent upon the rate of uptake of fluorocarbon from the alveolar airspace of the lung into blood and its delivery, primarily, to the liver. Metabolism was described in the PB-PK model by a linear first order rate constant of 8.98 hr" 1 which is in good accord with the experimentally derived values (Table 4) .
From the known routes of metabolism of dihalomethanes The PB-PK model predicts that during a 6-hr exposure of rats to HFC32 at concentrations of 10,000 to 50,000 ppm about 2.1% of the inhaled dose is absorbed systemically and is available for metabolism. Based on the recovery of radiolabel in urine and as CO2, approximately 1.4% of the inhaled dose was metabolized. However, when metabolism is expressed in terms of the absorbed dose approximately 63% of the HFC32 entering systemic circulation was metabolized.
In conclusion, HFC32 was of low toxicity by inhalation, slight maternal toxicity to pregnant rat and rabbit, and some fetotoxicity to the rat was observed. HFC32 did not sensitize the heart to adrenaline. HFC32 was not genotoxic. Investigation of the pharmacokinetics and metabolism of HFC32, at exposure concentrations similar to those used in the toxicity studies, allow its lack of in vivo toxicity to be rationalized. HFC32 was poorly absorbed into the blood and there was no accumulation into organs or fat. Upon cessation of exposure blood levels rapidly fall. Metabolism was oxidative and the putative intermediates elicit no organ-specific toxicity. CO 2 was the major metabolite of HFC32. The presence of nonvolatile urinary metabolites of HFC32 may indicate some incorporation of HFC32 into endogenous biomolecules via the C-l pool. At the concentrations investigated, approximately 63% of the HFC32 entering systemic circulation was metabolized, equivalent to about 1.4% of the HFC32 entering the airways.
